Download Image
    
Share
  
Post
Ensifentrine for COVID-19
1 study with 45 patients
Hospital Icon Control
Hospital Icon Ensifentrine Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Ensifentrine studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -150% Mortality -150% RCTs -150% Late -150% Favorsensifentrine Favorscontrol
Ensifentrine is a small-molecule dual PDE3/4 inhibitor with bronchodilator and anti-inflammatory effects.
May 1
2021
 MacDonald-Berko et al., NCT04527471 A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19
150% higher mortality (p=1) and 150% worse recovery (p=1). RCT 45 hospitalized COVID-19 patients showing no significant difference with ensifentrine treatment.